Last reviewed · How we verify
177Lu-BetaBart
Targeting somatostatin receptors
Targeting somatostatin receptors Used for Neuroendocrine tumors.
At a glance
| Generic name | 177Lu-BetaBart |
|---|---|
| Also known as | RV-01, B335 177Lu-DOTA-anti-B7-H3 |
| Sponsor | Radiopharm Theranostics, Ltd |
| Drug class | Somatostatin receptor-targeting radioligand |
| Target | Somatostatin receptors |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 1 |
Mechanism of action
177Lu-BetaBart is a radioligand therapy that selectively targets and binds to somatostatin receptors on neuroendocrine tumors, delivering cytotoxic radiation to the tumor cells.
Approved indications
- Neuroendocrine tumors
Common side effects
- Nausea
- Vomiting
- Fatigue
Key clinical trials
- 177Lu-BetaBart in Patients With Relapsed/Refractory, Locally Advanced Inoperable, or Metastatic Solid Tumors (PHASE1, PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- 177Lu-BetaBart CI brief — competitive landscape report
- 177Lu-BetaBart updates RSS · CI watch RSS
- Radiopharm Theranostics, Ltd portfolio CI